Dabrafenib and trametinib in Langerhans cell histiocytosis and other histiocytic disorders
The standard treatment for Langerhans cell histiocytosis (LCH) is chemotherapy, although the failure rates are high. Since MAP-kinase activating mutations are found in most cases, BRAF- and MEK-inhibitors have been used successfully to treat patients with refractory or relapsed disease. However, data on long-term responses in children are limited and there are no data on the use of these inhibitors as first-line therapy. We treated 34 patients (26 with LCH, 2 with juvenile xanthogranuloma, 2 with Rosai-Dorfman disease, and 4 with presumed single site-central nervous system histiocytosis) with dabrafenib and/or trametinib, either as first line or after relapse or failure of chemotherapy. Sixteen patients, aged 1.3-21 years, had disease that was recurrent or refractory to chemotherapy, nine of whom had multisystem LCH with risk-organ involvement. With a median treatment duration of 4.3 years, 15 (94%) patients have sustained favorable responses. Eighteen patients, aged 0.2-45 years, received an inhibitor as first-line treatment. All of these have had sustained favorable responses, with a median treatment duration of 2.5 years. Three patients with presumed isolated central nervous system/pituitary stalk histiocytosis had stabilization or improvement of their disease. Overall, inhibitors were well tolerated. Five patients with single-system LCH discontinued therapy and remain off therapy without recurrence. In contrast, all four patients with multisystem disease who discontinued therapy had to restart treatment. Our data suggest that children suffering from histiocytoses can be treated safely and effectively with dabrafenib or trametinib. Additional studies are, however, needed to determine the long-term safety and optimal duration of therapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:109 |
|---|---|
| Enthalten in: |
Haematologica - 109(2024), 4 vom: 01. Apr., Seite 1137-1148 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cournoyer, Eily [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
33E86K87QN |
|---|
| Anmerkungen: |
Date Completed 03.04.2024 Date Revised 04.04.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3324/haematol.2023.283295 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362280991 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362280991 | ||
| 003 | DE-627 | ||
| 005 | 20240404234302.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3324/haematol.2023.283295 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1364.xml |
| 035 | |a (DE-627)NLM362280991 | ||
| 035 | |a (NLM)37731389 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cournoyer, Eily |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Dabrafenib and trametinib in Langerhans cell histiocytosis and other histiocytic disorders |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.04.2024 | ||
| 500 | |a Date Revised 04.04.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The standard treatment for Langerhans cell histiocytosis (LCH) is chemotherapy, although the failure rates are high. Since MAP-kinase activating mutations are found in most cases, BRAF- and MEK-inhibitors have been used successfully to treat patients with refractory or relapsed disease. However, data on long-term responses in children are limited and there are no data on the use of these inhibitors as first-line therapy. We treated 34 patients (26 with LCH, 2 with juvenile xanthogranuloma, 2 with Rosai-Dorfman disease, and 4 with presumed single site-central nervous system histiocytosis) with dabrafenib and/or trametinib, either as first line or after relapse or failure of chemotherapy. Sixteen patients, aged 1.3-21 years, had disease that was recurrent or refractory to chemotherapy, nine of whom had multisystem LCH with risk-organ involvement. With a median treatment duration of 4.3 years, 15 (94%) patients have sustained favorable responses. Eighteen patients, aged 0.2-45 years, received an inhibitor as first-line treatment. All of these have had sustained favorable responses, with a median treatment duration of 2.5 years. Three patients with presumed isolated central nervous system/pituitary stalk histiocytosis had stabilization or improvement of their disease. Overall, inhibitors were well tolerated. Five patients with single-system LCH discontinued therapy and remain off therapy without recurrence. In contrast, all four patients with multisystem disease who discontinued therapy had to restart treatment. Our data suggest that children suffering from histiocytoses can be treated safely and effectively with dabrafenib or trametinib. Additional studies are, however, needed to determine the long-term safety and optimal duration of therapy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a dabrafenib |2 NLM | |
| 650 | 7 | |a QGP4HA4G1B |2 NLM | |
| 650 | 7 | |a trametinib |2 NLM | |
| 650 | 7 | |a 33E86K87QN |2 NLM | |
| 650 | 7 | |a Imidazoles |2 NLM | |
| 650 | 7 | |a Oximes |2 NLM | |
| 650 | 7 | |a Proto-Oncogene Proteins B-raf |2 NLM | |
| 650 | 7 | |a EC 2.7.11.1 |2 NLM | |
| 650 | 7 | |a Pyridones |2 NLM | |
| 650 | 7 | |a Pyrimidinones |2 NLM | |
| 700 | 1 | |a Ferrell, Justin |e verfasserin |4 aut | |
| 700 | 1 | |a Sharp, Susan |e verfasserin |4 aut | |
| 700 | 1 | |a Ray, Anish |e verfasserin |4 aut | |
| 700 | 1 | |a Jordan, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Dandoy, Christopher |e verfasserin |4 aut | |
| 700 | 1 | |a Grimley, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Roy, Somak |e verfasserin |4 aut | |
| 700 | 1 | |a Lorsbach, Robert |e verfasserin |4 aut | |
| 700 | 1 | |a Merrow, Arnold C |e verfasserin |4 aut | |
| 700 | 1 | |a Nelson, Adam |e verfasserin |4 aut | |
| 700 | 1 | |a Bartlett, Allison |e verfasserin |4 aut | |
| 700 | 1 | |a Picarsic, Jennifer |e verfasserin |4 aut | |
| 700 | 1 | |a Kumar, Ashish |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Haematologica |d 1947 |g 109(2024), 4 vom: 01. Apr., Seite 1137-1148 |w (DE-627)NLM000081892 |x 1592-8721 |7 nnns |
| 773 | 1 | 8 | |g volume:109 |g year:2024 |g number:4 |g day:01 |g month:04 |g pages:1137-1148 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3324/haematol.2023.283295 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 109 |j 2024 |e 4 |b 01 |c 04 |h 1137-1148 | ||